Hyperparathyroidism, Secondary Clinical Trial
— OPTIMALOfficial title:
Single-center, Open-label, Randomized Study of Anemia Management Improvement in End Stage Renal Disease (ESRD) Patients With Secondary Hyperparathyroidism
Clinical study aimed at improving anemia management in End Stage Renal Disease Patient (ESRD) on maintenance Hemodialysis with evidence of Chronic Kidney disease Mineral Bone Disorder (CKD-MBD)
Status | Recruiting |
Enrollment | 50 |
Est. completion date | March 2017 |
Est. primary completion date | December 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
INCLUSION CRITERIA. - Men and women - Age >18 years - Maintenance dialysis via Artero-Venous fistula - ESA use - iPTH between 300-600 pg/ml - Hb between 10.0-11.5 - Kt/V greater/equal than 1.2 - Signed informed consent prior to the initiation of the study EXCLUSION CRITERIA: None. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
Italy | Azienda Ospedaliera Sant'Anna | San Fermo della battaglia (CO) |
Lead Sponsor | Collaborator |
---|---|
Azienda Ospedaliera Sant'Anna | Amgen |
Italy,
Capuano A, Serio V, Pota A, Memoli B, Andreucci VE. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients. J Nephrol. 2009 Jan-Feb;22(1):59-68. — View Citation
Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol. 2006 Nov;1(6):1205-10. Epub 2006 Sep 6. — View Citation
Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005 Sep;68(3):1337-43. — View Citation
Gilbertson DT, Ebben JP, Foley RN, Weinhandl ED, Bradbury BD, Collins AJ. Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol. 2008 Jan;3(1):133-8. Epub 2007 Nov 28. — View Citation
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009 Aug;(113):S1-130. doi: 10.1038/ki.2009.188. — View Citation
Lacson E Jr, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis. 2003 Jan;41(1):111-24. — View Citation
National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003 Oct;42(4 Suppl 3):S1-201. — View Citation
Pisoni RL, Bragg-Gresham JL, Young EW, Akizawa T, Asano Y, Locatelli F, Bommer J, Cruz JM, Kerr PG, Mendelssohn DC, Held PJ, Port FK. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004 Jul;44(1):94-111. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | percent reduction in weekly ESA consumption to maintain Hb levels within the recommended range 10.0-11.5 g/dl | Primary objective: to test whether a tighter PTH control to achieve a PTH level lower than 300 pg/ml vs PTH levels between 300-540 pg/ml is associated with a lower ESA dose use to achieve the target Hb of 10.0-11.5 g/dl | baseline and after 12 months of followup | No |
Secondary | Change in iron status and storage. | Secondary objective: to test whether a tighter PTH control to achieve a PTH level lower than 300 pg/ml vs PTH levels between 300-540 pg/ml is associated with a better iron storage and mobilization. | baseline and after 12 months of followup | No |
Secondary | Difference in prevalence of cardiac valvular calcification progression detected by echocardiography between groups. | Secondary objective: to test whether a tighter PTH control to achieve a PTH level lower than 300 pg/ml vs PTH levels between 300-540 pg/ml is associated with cardiac valves deposition and progression attenuation. | baseline and after 12 months of followup | No |
Secondary | Difference in pulse wave velocity assessed by applanation tonometry between groups. | Secondary objective: to test whether a tighter PTH control to achieve a PTH level lower than 300 pg/ml vs PTH levels between 300-540 pg/ml is associated with arterial stiffness increase attenuation | baseline and after 12 months of followup | No |
Secondary | CKD-MBD control | Secondary objective: to test whether a tighter PTH control to achieve a PTH level lower than 300 pg/ml vs PTH levels between 300-540 pg/ml is associated with a better CKD-MBD control | baseline and after 12 months of followup | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01134562 -
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
|
Phase 1 | |
Completed |
NCT02523209 -
Analysis of Bone Microarchitecture With HR-pQCT of Patients With Chronic Kidney Disease (CKD) Candidates for Renal Transplantation
|
N/A | |
Completed |
NCT01922843 -
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
|
Phase 2 | |
Completed |
NCT01651000 -
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
|
Phase 3 | |
Completed |
NCT00528788 -
How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis
|
Phase 4 | |
Completed |
NCT01181531 -
Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis
|
Phase 4 | |
Completed |
NCT05382988 -
Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy
|
Phase 3 | |
Completed |
NCT02056730 -
The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid
|
Phase 4 | |
Completed |
NCT01704079 -
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
|
Phase 3 | |
Completed |
NCT00397475 -
Evaluation of Colecalciferol Substitution in Dialysis Patients
|
N/A | |
Withdrawn |
NCT03063190 -
Cholecalciferol Supplementation in Restless Leg Syndrome in Patients With Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT02102204 -
Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis
|
Phase 3 | |
Completed |
NCT01788046 -
Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis
|
Phase 3 | |
Completed |
NCT01785849 -
Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis
|
Phase 3 | |
Terminated |
NCT01277510 -
Pediatric Chronic Kidney Disease Safety and Efficacy
|
Phase 3 | |
Terminated |
NCT01439867 -
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
|
Phase 2 | |
Completed |
NCT01134549 -
Safety, Tolerability and Pharmacokinetics of KAI-4169 in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT01785875 -
Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis
|
Phase 3 | |
Active, not recruiting |
NCT02464072 -
Subtotal Parathyroidectomy or Total Parathyroidectomy With Autograft in Chronic Kidney Disease Patients Under Dialysis
|
N/A | |
Completed |
NCT01290029 -
Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease
|
Phase 1 |